Potassium inwardly rectifying channel subfamily J member 8 (Kir6.1) (Kir6.1)

Potassium inwardly rectifying channel subfamily J member 8 (Kir6.1), encoded by the KCNJ8 gene, is a critical pore-forming subunit of the ATP-sensitive potassium (KATP) channel (UniProt, NIH). It typically forms a hetero-octameric complex with the sulfonylurea receptor 2 (SUR2B) in vascular smooth muscle, where it serves as a metabolic sensor that couples the cellular energy state to membrane excitability (PubMed, NIH). When intracellular ATP levels drop or ADP levels rise, the channel opens, causing potassium efflux and membrane hyperpolarization, which results in vasodilation and blood pressure reduction (PubMed, Wikipedia). Beyond its role in the vasculature, Kir6.1 is involved in cardiac protection during ischemia and neurovascular coupling in the brain (PubMed, NIH). Mutations in KCNJ8 are linked to several genetic disorders, including Cantú syndrome (gain-of-function) and J-wave syndromes like Brugada syndrome (PubMed, NIH). Pharmacological modulation of Kir6.1 with openers is primarily used for treating hypertension and angina, while its inhibition is a known side effect of certain sulfonylureas used in diabetes management (PubMed, NIH).

Other names

KCNJ8Kir6.1uKATP-1ATP-sensitive inward rectifier potassium channel 8Inward rectifier K(+) channel Kir6.1

Drugs targeting Kir6.1 act as either openers (activators) or blockers (inhibitors) of the ATP-sensitive potassium (KATP) channel (PubMed). Openers, such as pinacidil, facilitate the efflux of potassium ions, which hyperpolarizes the cell membrane and leads to the relaxation of vascular smooth muscle, resulting in vasodilation (PubMed, NIH). Conversely, blockers like glibenclamide or PNU-37883A inhibit the channel, preventing potassium efflux and promoting membrane depolarization (PubMed).